Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CB-183,315

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Objectives The effects of surotomycin (CB-183,315, MK-4261), a bactericidal cyclic lipopeptide, and vancomycin, the current… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
2015
2015
ABSTRACT Surotomycin (CB-183,315), a cyclic lipopeptide, is in phase 3 clinical development for the treatment of Clostridium… Expand
2015
2015
OBJECTIVES Clostridium difficile infection (CDI) is the leading cause of hospital-acquired diarrhoea in developed countries… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
2014
2014
ABSTRACT Surotomycin (CB-183,315) is an orally administered, minimally absorbed, selective bactericidal cyclic lipopeptide in… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2012
Highly Cited
2012
ABSTRACT CB-183,315 is a novel lipopeptide antibiotic structurally related to daptomycin currently in phase 3 clinical… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2012
Highly Cited
2012
ABSTRACT We evaluated the activity of CB-183,315 against Clostridium difficile, including strains that are resistant to… Expand
  • table 1
  • table 2
Highly Cited
2011
Highly Cited
2011
ABSTRACT MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal… Expand
  • table 1
2011
2011
  • L. Laursen
  • Nature Biotechnology
  • 2011
  • Corpus ID: 39851687
Companies seeking approval for new biotech crops can now prepare their own environmental study or hire an outside contractor to… Expand
  • table 1